US5616361A - Process for the production of a xylitol-based binding and diluting agent - Google Patents

Process for the production of a xylitol-based binding and diluting agent Download PDF

Info

Publication number
US5616361A
US5616361A US08/616,182 US61618296A US5616361A US 5616361 A US5616361 A US 5616361A US 61618296 A US61618296 A US 61618296A US 5616361 A US5616361 A US 5616361A
Authority
US
United States
Prior art keywords
xylitol
weight
sorbitol
tablets
granulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/616,182
Inventor
Jouko Virtanen
Matti Makela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco Sweeteners Oy
Original Assignee
Cultor Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI880092A external-priority patent/FI880092A/en
Application filed by Cultor Oyj filed Critical Cultor Oyj
Priority to US08/616,182 priority Critical patent/US5616361A/en
Application granted granted Critical
Publication of US5616361A publication Critical patent/US5616361A/en
Assigned to XYROFIN OY reassignment XYROFIN OY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CULTOR LTD.
Assigned to XYROFIN OY reassignment XYROFIN OY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DANISCO FINLAND OY
Assigned to DANISCO SWEETENERS OY reassignment DANISCO SWEETENERS OY CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: XYROFIN OY
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/02Monosaccharides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/346Finished or semi-finished products in the form of powders, paste or liquids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30Artificial sweetening agents
    • A23L27/33Artificial sweetening agents containing sugars or derivatives
    • A23L27/34Sugar alcohols
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A23L29/37Sugar alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G2200/00COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
    • A23G2200/06COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing beet sugar or cane sugar if specifically mentioned or containing other carbohydrates, e.g. starches, gums, alcohol sugar, polysaccharides, dextrin or containing high or low amount of carbohydrate

Definitions

  • This invention relates to a free flowing, compressible granulate which contains xylitol in combination with another polyol, preferably sorbitol.
  • the composition of the instant invention is particularly suitable for use in the manufacture of tablets by direct compression means.
  • the present invention also contemplates a method for the production of a free flowing, compressible granulate containing xylitol and another polyol (preferably sorbitol) which is suitable for use in the manufacture of tablets by direct compression means.
  • sucrose The most commonly used sweetener for food and pharmaceutical contexts is sucrose.
  • Sucrose is used for its well-known sweetening properties and also for bulking purposes. Although a wide variety of alternate sweeteners are available, sucrose is generally considered to be the optimum sweetener with regard to taste profile and technological properties. However, sucrose has been implicated as a contributory factor in many diseases including hypertension, coronary heart disease, arterial sclerosis and dental caries. These health concerns have led health care professionals to analyze the effects of sucrose and its prominent role in the diet.
  • sucrose is its contribution to tooth decay.
  • the mouth contains a number of bacterial strains which ferment common dietary carbohydrates such as sucrose. This fermentation generates acid as an end product which lowers the pH in the mouth; the lowered pH leads to a demineralization of tooth enamel and finally to the formation of dental lesions or caries.
  • Xylitol has been used as a sugar substitute in certain contexts (e.g. chewing gum: U.S. Pat. Nos. 4,514,422 (Yang) and 3,422,184 (Patel)) with practical and commercial success.
  • the use of xylitol is attractive because of its taste and technological advantages.
  • Xylitol is a naturally occurring five carbon sugar alcohol which has the same sweetness as sugar and a caloric content which is less than that of sugar.
  • Xylitol is found in small amounts in many fruits and vegetables and is produced in the human body during normal metabolism. Xylitol is particularly attractive because of its known metabolic, dental and technical characteristics.
  • xylitol is metabolized largely independent of insulin, so it can be safely consumed by noninsulin dependent diabetics. Further, xylitol has been shown to delay gastric emptying and to possibly suppress food intake which means it may have an important role in weight reducing diets.
  • xylitol is not fermented by S. mutans and other bacteria found in the mouth and, therefore, does not produce acids which, as described herein, contribute to the formation of dental caries.
  • Xylitol is well established as a non-cariogenic substance, i.e. xylitol does not contribute to caries formation.
  • Significant data also exists which supports the view that xylitol is not only non-cariogenic, but actively suppresses the formation of new caries and may even reverse existing lesions by inducing remineralization, i.e. it is a cariostatic material.
  • Xylitol also has significant technological advantages, particularly with respect to taste profile. Xylitol produces a pleasant cooling effect in the mouth when consumed in the crystalline state. The energy required to dissolve one gram of xylitol is 34.6 calories, the highest known value for sugars and sugar alcohols; this produces a physical cooling effect which is desirable in many contexts. Xylitol is as sweet as sugar and does not typically manifest unpleasant aftertastes.
  • polystyrene resin such as sorbitol, mannitol, lactitol and others have also been substituted for sucrose in a variety of contexts. All of these polyols have certain advantages--such as non-cariogenicity--over sucrose. However, none of the other polyols have been demonstrated to have a cariostatic effect.
  • xylitol has been heretofore utilized with only limited success is as a constituent in tablets.
  • tablets are used for bringing active substances into a size, shape and texture that can be dosaged, chewed, sucked, swallowed whole or dissolved in water for drinking.
  • tablets can take the form of compressed, fruit or mint flavored confections which consist of a sweetener(s), flavor(s). and optionally color and acid. Because of its taste and cariostatic properties as described above, xylitol is a potentially attractive constituent in tablets for both food and pharmaceutical purposes. Xylitol has not been extensively utilized as a binding or diluting agent in this context.
  • Sweetness in pharmaceutical tablets fulfills the purpose of making the product more pleasant to eat and to mask any unpleasant taste of the active ingredient(s).
  • Today, many pharmaceutical tablets are sweetened with sucrose, lactose and other fermentable carbohydrates which are also used as diluents.
  • Replacing sucrose and other fermentable carbohydrates with xylitol in those applications which must be sweetened would eliminate the use of cariogenic formulations in medicaments such as throat lozenges, cough tablets, vitamins, chewable tablets and others, and also takes advantage of the other attributes of xylitol discussed above, such as its noted cooling effect and metabolic characteristics.
  • sucrose is the sweetener of choice in these contexts and has bulking properties as well. Replacing sucrose with xylitol would enable tablets to exploit the unique advantages of xylitol, particularly its anti-caries properties, and its pronounced cooling effect.
  • xylitol The cariostatic effect of xylitol is particularly important because clinical studies have shown that it is not the quantity of sucrose (or other acid producing substances such as maltose, lactose and dextrose), but the frequency of sucrose intake that is critical for caries development. Many pharmaceutical and food tablets are designed to be and are consumed at frequent and/or regular intervals throughout the day. For this reason, some dental researchers have suggested switching from sucrose, maltose, lactose, dextrose to a non-acid producing sweetener such as xylitol in pharmaceutical and food contexts.
  • Tablets can be formed by compression or by molding.
  • a representative tablet press is a MANESTY Novapress, manufactured by Manesty Machines Ltd., Liverpool, England, and many others are available.
  • binding and diluting agents are used to permit direct compression to take place.
  • An ideal binding and diluting agent also functions in the tablet either as an active ingredient or as an agent which contributes or improves flavor or other properties.
  • free flowing means that the particles to be compressed must enter the compression chamber as discreet particles; compressible means the particles form a tablet after compression and do not remain in a powdered or substantially powdered form.
  • Friability is also a standard test known to one skilled in the art. Friability is measured under standardized conditions by weighing out a certain number of tablets (generally 20 or more), placing them in a rotating plexiglass drum in which they are lifted during replicate revolutions by a radial louver, and then dropped through the diameter of the drum. After replicate revolutions, the tablets are reweighed and the percentage of powder "rubbed off” or broken pieces is calculated. Friability in the range of about 0% to 3% is considered acceptable for most drug and food tablet contexts. Friability which approaches 0% is particularly preferred.
  • Tablets of insufficient hardness exhibit capping and/or lamination and can easily break apart or disintegrate under normal handling and packaging conditions. Tablets of insufficient hardness cannot be used for lozenges or mints which are designed to be sucked in the mouth, releasing the active ingredient(s) or flavor over time, and may have an undesirable powdery, grainy or coarse mouthfeel.
  • Sweet carbohydrates such as sugars and sugar alcohols are well suited for use as binding and diluting agents, particularly because they can function as an active ingredient or as a flavor improving agent.
  • crystalline or powdered sugars and sugar alcohols as such are poorly suited for direct compression techniques because they have poor flowability and/or compressibility. Therefore, granulated sugars or sugar alcohols have been developed for use in direct compression. In pharmaceutical and food industries, granulated forms can be regarded as semi-finished products which are utilized as raw materials in effective tableting techniques.
  • binding and diluting agents which contain sugars.
  • commercial binding and diluting agents include an agglomerated dextrose product sold under the trademark EMDEX, an agglomerated sucrose product containing dextrines sold under the trademark DIPAC and a pregelatinized directly compressible starch and mannitol product sold under the trademark STARCH 1500.
  • Finnish Patent Application No. 854,885 discloses a fructose-based binding and diluting agent namely, a fructose agglomerate, suited for use in direct compression tableting techniques.
  • U.S. Pat. No. 4,159,345 to Takeo et al. discloses an excipient consisting essentially of microcrystalline cellulose having certain characteristics.
  • Xylitol is not considered to be directly compressible, i.e. crystalline xylitol cannot be compressed into tablets of sufficient hardness and low friability. Therefore, in order to utilize xylitol in tablets, a variety of approaches to impart these characteristics have been used, without complete success.
  • One method has been to compress xylitol into tablets of relatively low initial hardness (e.g. about 6 S.C.U.) and "finish" the outer surface.
  • the finishing step takes advantage of the unique crystallization properties of xylitol and its low melting point.
  • This finishing step adds another significant step to the production process (thereby increasing the cost and decreasing the efficiency), cannot be used in all tablet contexts, and does not result in a tablet with uniform hardness.
  • Tablets can be formed with xylitol by means of the conventional wet granulation process with gelatin or starch as an additive. Xylitol has also been admixed with other polyols to form a mixture which is then compressed.
  • U.K. Patent No. 1,526,020 to Lifesavers, Inc. discloses a process for the preparation of a tablet containing xylitol utilizing direct compression techniques. In the examples of the patent specification (which disclose the use of xylitol in combination with at least one other polyol), the ratio of xylitol/sorbitol is 1:1 to about 0.43:1 (256:297), and the ratio of xylitol/mannitol is also 1:1.
  • the examples enable only a partial utilization of the anti-cariogenic affect, and advantageous flavoring properties of xylitol, because a major portion of the tablet consists of sorbitol which does not show xylitol's taste and anti-cariogenic qualities.
  • crystalline xylitol produces tablets which are too coarse in many contexts which give rise to a gritty texture and undesirable mouthfeel.
  • milled xylitol (less than 200 micron average particle size) produces a dry blended product (with sorbitol, for example) wherein flowability of the blend is extremely poor (near zero). Tableting machinery equipped with a force feeder is required. Dry blended xylitol and sorbitol is not an acceptable commercial alternative.
  • the present invention discloses a free flowing, compressible granulate which comprises at least 94% to 98% by weight of xylitol in combination with another physiologically accepted polyol, preferably sorbitol. Sorbitol does not diminish the cooling effect of xylitol (as other constituents may) and also acts as a lubricant in the direct compression context.
  • the granulate is suitable for use as a binding or diluting agent in direct compression techniques.
  • the present invention also contemplates a method for producing such a xylitol-based granulate.
  • the present invention contemplates a free flowing, compressible granulate which comprises about 94% to about 98% by weight of xylitol, about 1% to about 5% by weight of a physiologically acceptable polyol other than xylitol, and less than about 1% by weight of water.
  • the polyol does not contribute appreciable moisture to said granulate, nor does it negatively affect the taste profile of xylitol.
  • the free flowing, compressible granulate comprises about 95% to about 98% by weight of xylitol, about 1.5% to about 3.5% by weight of a physiologically acceptable polyol other than xylitol, and less than about 0.5% by weight of water.
  • the physiologically acceptable polyol of choice is sorbitol, and other polyols such as mannitol, lactitol, maltitol and isomalt can also be used. If sorbitol is utilized, the present invention also contemplates a composition which comprises xylitol, sorbitol and less than about 2% of a physiologically acceptable polyol or polyols other than sorbitol, e.g. mannitol, which does not contribute appreciable moisture, or negatively affect the taste profile of xylitol.
  • the bulk density of the composition of the present invention is between about 0.7 g/cm 3 and about 0.8 g/cm 3 .
  • the average particle size is between about 0.1 mm and about 1.0 mm.
  • the composition exhibits good flow properties, preferably exhibiting a flow range with a maximum of about 15 s/100 g.
  • the present invention also contemplates a method for the production of a free flowing, compressible granulate wherein finely ground xylitol crystals are agglomerated with a polyol based syrup to obtain granules which are subsequently dried to a water content of less than about 1% by weight.
  • the polyol does not contribute an appreciable amount of moisture, nor does it negatively affect the taste profile of xylitol.
  • the composition in a preferred embodiment, comprises about 94% to about 98% by weight of xylitol and between about 1% and about 5% by weight of a physiologically acceptable polyol with water present in amounts of less than 1% by weight.
  • the ground xylitol has a particle size of about 0.01 mm to about 0.10 mm, with at least about 50% of said xylitol particles within that range.
  • the average particle size of the xylitol is about 0.07 mm, with at least about 50% of said xylitol having a particle size of between about 0.02 mm to about 0.10 mm.
  • the polyol based syrup used for the agglomerating step preferably is based on sorbitol, with a syrup containing between about 50% and about 85% of sorbitol by weight being particularly preferred.
  • the binding and diluting agent of the present invention is a granulated product which has a good flowability and which is prepared by agglomerating crystalline xylitol (ground or otherwise comminuted to a small particle size) by means of polyol based syrup wherein said polyol is a physiologically acceptable polyol other than xylitol.
  • the xylitol is mixed with the syrup at a great speed to obtain a granular product; the granules are subsequently dried to a water content less than 1.0% by weight.
  • the concentration of the physiologically acceptable polyol based syrup is selected so that the obtained granular product contains between about 94% and 98% by weight of xylitol and about 1% to 5% by weight of said physiologically acceptable polyol (other than xylitol).
  • the preferred physiologically acceptable polyol is sorbitol because it does not negatively affect the taste profile of xylitol.
  • the granular product may also contain physiologically acceptable polyols other than xylitol and sorbitol, preferably less than about 2% by weight, provided such polyols do not contribute appreciably to the moisture content, or negatively affect the taste profile of xylitol.
  • the flowability of the present invention agent can be measured by allowing a sample (200 g) to flow through a hopper (runner pipe dimensions: diameter 8 mm and length 25 mm) on to a balance connected to a recording device.
  • the flowability (s/100 g) of the substance can thus be calculated from the curve so obtained.
  • the flowability should ideally be better than 15 s/100 g.
  • Another procedure for evaluating flowability is the determination of angle of repose: a sample (50 g) is passed slowly through a hopper on to a paper, and the angle defined between the paper and the formed hill is measured. This angle should not exceed 32°.
  • the bulk density of the substance can be measured by weighing a sample of about 300 g into a measuring cylinder. The sample is poured carefully into the cylinder; the sample is weighed accurately and its volume is recorded. The loose density (LD) can be calculated from this data. Thereafter the sample is vibrated at an amplitude of 1.5 mm, until it does not pack to a smaller volume. The volume is recorded, and the bulk density (also known as tapped density or "TD") is calculated.
  • LD loose density
  • Xylitol used as raw material in the production of the binding and diluting agent according to the invention has a purity exceeding 95% by weight, and has been ground or otherwise comminuted to an average particle size of between 0.01 mm to 0.10 mm by means of a suitable mill, such as a hammer mill common in the sugar industry to produce icing sugar.
  • sorbitol is added to the xylitol at the granulation stage in the form of sorbitol syrup which may be e.g. hydrogenated starch syrup containing about 50% to 90% by weight of sorbitol on dry substance basis, the remainder consisting of other sugar alcohols. Pure dissolved sorbitol is also suitable for use.
  • Sorbitol syrup is diluted before granulation so that the dry substance content of the solution suits the granulation device.
  • the nozzle structure of the Schugi device for instance, requires a dry content below 50% by weight.
  • the dry substance content of a commercial sorbitol syrup generally varies from 69% to 71% by weight.
  • the dilution is preferably carried out with water, though a mixture of water and ethanol is also possible. The use of ethanol, however, is restricted by the poor solubility of sorbitol in ethanol.
  • a preferred method for preparing the present invention consists of granulating the ground or comminuted xylitol together with a small amount of sorbitol syrup by means of a suitable granulation device.
  • the product is dried rapidly in a fluidized bed, for instance.
  • Suitable granulation devices are well known in the art.
  • the dryer may be separate, or the drying may be carried out in a granulator, depending on the type of device.
  • the ground or comminuted xylitol and the sorbitol syrup added evenly thereto are brought into a rapid movement which effects the agglomeration of the substance together with a small amount of syrup.
  • the grain size can be adjusted by the mixture ratios and the mixing efficiency.
  • the granulated product is dried rapidly e.g. in a fluidized bed by means of dry air so that the final moisture content is below about 1% by weight, preferably below about 0.5% by weight.
  • a suitable particle size is between about 0.1 mm to about 1 mm whereby about 99% of the granules are within this range.
  • dry air refers to air with a water content no more than 7.5 grams of water per cubic meter of air, measured at 20° C.
  • the product obtained according to the invention is a freely flowing, compressible composition which has excellent compressibility and which withstands storing without getting cloddy.
  • the preferred range of properties for one embodiment are as follows:
  • Average grain size (diameter) about 0.1 mm to about 0.6 mm
  • Sorbitol about 2% to about 3% by weight
  • the granulation process is fundamentally different from the dry mixing of two polyols such as xylitol and sorbitol, such as that disclosed by G.B. Patent Nos. 1,526,020.
  • the granulation process results in the crystallization of some of the sorbitol or present onto the surface of the xylitol particles forming fine, needle like protrusions.
  • These needle like protrusions can be seen by electron microscopes, and a photograph showing the granulate of the present invention (with xylitol present in an amount of about 97% by weight, and sorbitol present in an amount of about 3% by weight) is shown in FIG. 1; the needle like crystals can be clearly seen.
  • Blends of xylitol and sorbitol in the proportion covered by the present invention which are simply admixed do not exhibit adequate compressibility and do not exhibit the needle like protrusions in electron micrographs such as those seen in FIG. 1.
  • Tablets made from pure crystalline xylitol show extremely poor hardness. At a force of 25 kN, 100% xylitol tablets exhibited a crushing strength less than 25 N. Only when sorbitol was present in amounts exceeding 40% by weight did the crushing strength exceed 100 N at a crushing strength of 25 kN.
  • the present invention allows the use of high concentrations of xylitol thereby taking full advantage of its taste, metabolic and other advantages.
  • Crystalline xylitol (purity over 95% by weight) was ground by means of a turbo mill (Bauermeister, manufacturer Gebr. Bauerffle & Co., Hamburg, West Germany) to an average particle size of about 0.07 mm. Over 50% of the particles were within the range from about 0.02 mm to about 0.10 mm, and the powder did not contain any particles exceeding 0.125 mm, nor a dusty fraction.
  • Example 2 Granulation of Xylitol Powder
  • a xylitol powder produced according to Example 1 and a 40% by weight sorbitol syrup solution (containing 34% by weight of sorbitol, and less than 5.7% of other polyols) were introduced into a granulator (Schugi, manufacturer Schugi, BV, Lelystad, Holland) at a speed of 800 kg/hour (powder) and 50 1/hour (syrup solution) at a temperature of 60° C.
  • the spraying pressure was 2 bar and the rotative velocity 3,000 r/min, whereby grains having an average diameter of 0.42 mm were obtained (over 50% within the range of 0.2 to 0.6 mm).
  • the resultant grains were dried with a fluidized-bed dryer (Schugi, manufacturer Schugi, BV, Lelystad, Holland). Granulate was fed into the dryer at a rate of 820 kg/h, and 10,000 m 3 /hour of dry air was introduced therein.
  • the temperature of the drying air in the first quarter of the dryer was 45° C. and in the second quarter 35° C.; in the last two quarters of the dryer the temperature was room temperature, i.e. 20° C. to 25° C.
  • the moisture content of the product was about 0.3% by weight, and the bulk density (TD) was about 0.74 g/ml.
  • composition of the product was as follows:
  • the flowability of the granulate produced according to Example No. 2 was extremely good (flow rate 12 s/100 g; flow angle 30°), and the properties of the granulate did not change during storage (75 days, 18° C.).
  • the granulate produced according to Example 2 was compressed to tablets by means of an eccentric press (Korsch EK-O/DMS; manufacturer Korch OHC Maschinenfabrick, Berlin, West Germany). Magnesium stearate (1%) was used as an additive. The diameter of the tablet was 11 mm and weight 500 mg. The crushing strength of tablets manufactured by different compression forces was determined in accordance with the instructions of the European Pharmacopean. The results are shown in Table 1.
  • a granulate produced according to Example 2 was compressed to double-convex tablets by means of a rotation machine (Manesty D 3; manufacturer, Manesty Machines, Liverpool, England). Magnesium stearate (1%) was used as an additive.
  • the diameter of the tablet was 15 mm and weight 907 mg.
  • the crushing strength of the tablet (European Pharmacopea) was 127 N; the weight loss in friability tests was 0.71%.
  • Tablets prepared in Examples 3 and 4 had acceptable mouthfeel, initial hardness and friability.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a method for the production of a free flowing, compressible granulate which contains from 94% to 98% by weight of xylitol, another physiologically acceptable polyol such as mannitol, maltitol or isomalt and less than 1% by weight of water.

Description

This application is a continuation of U.S. patent application Ser. No. 08/079,794, filed Mar. 20, 1991, now U.S. Pat. No. 5,536,526 which is a continuation-in-part of U.S. patent application Ser. No. 07/314,766, filed Feb. 23, 1989, now abandoned.
TECHNICAL FIELD
This invention relates to a free flowing, compressible granulate which contains xylitol in combination with another polyol, preferably sorbitol. The composition of the instant invention is particularly suitable for use in the manufacture of tablets by direct compression means. The present invention also contemplates a method for the production of a free flowing, compressible granulate containing xylitol and another polyol (preferably sorbitol) which is suitable for use in the manufacture of tablets by direct compression means.
II. BACKGROUND OF THE INVENTION
A. The Advantages of Xylitol
The most commonly used sweetener for food and pharmaceutical contexts is sucrose. Sucrose is used for its well-known sweetening properties and also for bulking purposes. Although a wide variety of alternate sweeteners are available, sucrose is generally considered to be the optimum sweetener with regard to taste profile and technological properties. However, sucrose has been implicated as a contributory factor in many diseases including hypertension, coronary heart disease, arterial sclerosis and dental caries. These health concerns have led health care professionals to analyze the effects of sucrose and its prominent role in the diet.
Perhaps the most significant, well-documented effect of sucrose is its contribution to tooth decay. The mouth contains a number of bacterial strains which ferment common dietary carbohydrates such as sucrose. This fermentation generates acid as an end product which lowers the pH in the mouth; the lowered pH leads to a demineralization of tooth enamel and finally to the formation of dental lesions or caries.
It is well known that it is not the total quantity of sugar consumed per se, but the frequency of consumption that contributes to dental caries. Thus, the presence of sucrose and other fermentable carbohydrates in regular meals is not the principal cause of tooth decay. The consumption of fermentable carbohydrates between meals in the form of confections and sweetened pharmaceuticals (and the frequency of such consumption) have been shown to have a close relationship to the formation of dental caries. Long after the candy or drug has been consumed, the fermentable carbohydrate stays in the mouth and is fermented by Streptococcus mutans and other cariogenic bacteria, lowering the mouth pH and promoting dental caries as described above.
One approach to fighting dental caries is to reduce or eliminate the amount of fermentable carbohydrates such as sucrose in pharmaceutical or food contexts. The replacement of fermentable carbohydrates by sugar substitutes which cannot be fermented, or are less easily fermented by S. mutans and other bacteria has been shown to decrease the development of dental caries.
Xylitol has been used as a sugar substitute in certain contexts (e.g. chewing gum: U.S. Pat. Nos. 4,514,422 (Yang) and 3,422,184 (Patel)) with practical and commercial success. The use of xylitol is attractive because of its taste and technological advantages. Xylitol is a naturally occurring five carbon sugar alcohol which has the same sweetness as sugar and a caloric content which is less than that of sugar. Xylitol is found in small amounts in many fruits and vegetables and is produced in the human body during normal metabolism. Xylitol is particularly attractive because of its known metabolic, dental and technical characteristics.
From a metabolic perspective, xylitol is metabolized largely independent of insulin, so it can be safely consumed by noninsulin dependent diabetics. Further, xylitol has been shown to delay gastric emptying and to possibly suppress food intake which means it may have an important role in weight reducing diets.
A significant advantage of xylitol is that it is not fermented by S. mutans and other bacteria found in the mouth and, therefore, does not produce acids which, as described herein, contribute to the formation of dental caries. Xylitol is well established as a non-cariogenic substance, i.e. xylitol does not contribute to caries formation. Significant data also exists which supports the view that xylitol is not only non-cariogenic, but actively suppresses the formation of new caries and may even reverse existing lesions by inducing remineralization, i.e. it is a cariostatic material. A summary of clinical data regarding the effects of xylitol and its possible mechanisms is set forth in Bar, Albert, Caries Prevention With Xylitol: A Review of the Scientific Evidence, 55 Wld. Rev. Nutr. Diet. 183-209 (1983). The mechanism or mechanisms by which xylitol effects any cariostatic properties is not yet known, but some possible mechanisms which have been suggested include a reduction of oral levels of S. mutans, a reduction in the development of plaque, the stimulation of the flow of protective saliva, the favorable alteration of the composition of saliva, the retardation of demineralization and an enhancement of remineralization of tooth enamel.
Xylitol also has significant technological advantages, particularly with respect to taste profile. Xylitol produces a pleasant cooling effect in the mouth when consumed in the crystalline state. The energy required to dissolve one gram of xylitol is 34.6 calories, the highest known value for sugars and sugar alcohols; this produces a physical cooling effect which is desirable in many contexts. Xylitol is as sweet as sugar and does not typically manifest unpleasant aftertastes.
Other polyols, such as sorbitol, mannitol, lactitol and others have also been substituted for sucrose in a variety of contexts. All of these polyols have certain advantages--such as non-cariogenicity--over sucrose. However, none of the other polyols have been demonstrated to have a cariostatic effect.
One context in which xylitol has been heretofore utilized with only limited success is as a constituent in tablets. In pharmaceutical contexts, tablets are used for bringing active substances into a size, shape and texture that can be dosaged, chewed, sucked, swallowed whole or dissolved in water for drinking. In food contexts, tablets can take the form of compressed, fruit or mint flavored confections which consist of a sweetener(s), flavor(s). and optionally color and acid. Because of its taste and cariostatic properties as described above, xylitol is a potentially attractive constituent in tablets for both food and pharmaceutical purposes. Xylitol has not been extensively utilized as a binding or diluting agent in this context.
Sweetness in pharmaceutical tablets fulfills the purpose of making the product more pleasant to eat and to mask any unpleasant taste of the active ingredient(s). Today, many pharmaceutical tablets are sweetened with sucrose, lactose and other fermentable carbohydrates which are also used as diluents. Replacing sucrose and other fermentable carbohydrates with xylitol in those applications which must be sweetened would eliminate the use of cariogenic formulations in medicaments such as throat lozenges, cough tablets, vitamins, chewable tablets and others, and also takes advantage of the other attributes of xylitol discussed above, such as its noted cooling effect and metabolic characteristics.
In food contexts, tablets are usually sucked or chewed by the user and are often used as breath mints. Sucrose is the sweetener of choice in these contexts and has bulking properties as well. Replacing sucrose with xylitol would enable tablets to exploit the unique advantages of xylitol, particularly its anti-caries properties, and its pronounced cooling effect.
The cariostatic effect of xylitol is particularly important because clinical studies have shown that it is not the quantity of sucrose (or other acid producing substances such as maltose, lactose and dextrose), but the frequency of sucrose intake that is critical for caries development. Many pharmaceutical and food tablets are designed to be and are consumed at frequent and/or regular intervals throughout the day. For this reason, some dental researchers have suggested switching from sucrose, maltose, lactose, dextrose to a non-acid producing sweetener such as xylitol in pharmaceutical and food contexts.
B. Tableting Techniques and Tablets
Tablets can be formed by compression or by molding.
Modern compression tableting techniques--irrespective of the type (and ultimate shape of the end product)--utilize a piston like device with three stages in each cycle: (1) filling --adding the constituents of the tablet to the compression chamber; (2) compression--forming the tablet; and (3) ejection--removing the tablet. The cycle is then repeated. A representative tablet press is a MANESTY Novapress, manufactured by Manesty Machines Ltd., Liverpool, England, and many others are available.
Because many materials have some, or none, of the required qualities of "flowability" and "compressibility" binding and diluting agents have been developed to permit direct compression to take place. An ideal binding and diluting agent also functions in the tablet either as an active ingredient or as an agent which contributes or improves flavor or other properties. In this context, free flowing means that the particles to be compressed must enter the compression chamber as discreet particles; compressible means the particles form a tablet after compression and do not remain in a powdered or substantially powdered form.
Two critical criteria in the quality of a tablet are crushing strength (or hardness) and friability. The resistance of the tablet to chipping, abrasion, or breakage under conditions of storage, transportation and handling before usage depends on its hardness. Hardness is measured by determining lateral breaking strength (expressed in kilo pounds Strong Cobb Units wherein 1 kp=1.4 S.C.U.) exerted on a single tablet at the moment of rupture. A representative hardness tester is the Model HT-300 manufactured by Key International, Inc. Acceptable hardness depends on the desired mouthfeel and the expected end use and packaging conditions of the tablet, but in most contexts, tablet hardness must be greater than about 10 S.C.U. to be commercially useful.
Friability is also a standard test known to one skilled in the art. Friability is measured under standardized conditions by weighing out a certain number of tablets (generally 20 or more), placing them in a rotating plexiglass drum in which they are lifted during replicate revolutions by a radial louver, and then dropped through the diameter of the drum. After replicate revolutions, the tablets are reweighed and the percentage of powder "rubbed off" or broken pieces is calculated. Friability in the range of about 0% to 3% is considered acceptable for most drug and food tablet contexts. Friability which approaches 0% is particularly preferred.
Tablets of insufficient hardness exhibit capping and/or lamination and can easily break apart or disintegrate under normal handling and packaging conditions. Tablets of insufficient hardness cannot be used for lozenges or mints which are designed to be sucked in the mouth, releasing the active ingredient(s) or flavor over time, and may have an undesirable powdery, grainy or coarse mouthfeel.
Sweet carbohydrates such as sugars and sugar alcohols are well suited for use as binding and diluting agents, particularly because they can function as an active ingredient or as a flavor improving agent. However, crystalline or powdered sugars and sugar alcohols as such are poorly suited for direct compression techniques because they have poor flowability and/or compressibility. Therefore, granulated sugars or sugar alcohols have been developed for use in direct compression. In pharmaceutical and food industries, granulated forms can be regarded as semi-finished products which are utilized as raw materials in effective tableting techniques.
The prior art discloses binding and diluting agents which contain sugars. For example, commercial binding and diluting agents include an agglomerated dextrose product sold under the trademark EMDEX, an agglomerated sucrose product containing dextrines sold under the trademark DIPAC and a pregelatinized directly compressible starch and mannitol product sold under the trademark STARCH 1500. Finnish Patent Application No. 854,885 discloses a fructose-based binding and diluting agent namely, a fructose agglomerate, suited for use in direct compression tableting techniques. U.S. Pat. No. 4,352,821 to Doran et al. discloses a binding and diluting agent consisting of fructose and a water insoluble carrier consisting of an edible, inorganic salt. U.S. Pat. No. 4,159,345 to Takeo et al. discloses an excipient consisting essentially of microcrystalline cellulose having certain characteristics.
C. Use of Xylitol in Tablet Contexts
Xylitol is not considered to be directly compressible, i.e. crystalline xylitol cannot be compressed into tablets of sufficient hardness and low friability. Therefore, in order to utilize xylitol in tablets, a variety of approaches to impart these characteristics have been used, without complete success.
One method has been to compress xylitol into tablets of relatively low initial hardness (e.g. about 6 S.C.U.) and "finish" the outer surface. The finishing step takes advantage of the unique crystallization properties of xylitol and its low melting point. Basically, the compressed tablets--which have a low initial hardness--are heated by exposing the surface of the tablets to hot air at temperatures greater than 94° C. which cause a phase change in the xylitol from solid to liquid. After cooling, recrystallization occurs quickly and a "glass" hard surface layer is formed. This finishing step, however, adds another significant step to the production process (thereby increasing the cost and decreasing the efficiency), cannot be used in all tablet contexts, and does not result in a tablet with uniform hardness.
Tablets can be formed with xylitol by means of the conventional wet granulation process with gelatin or starch as an additive. Xylitol has also been admixed with other polyols to form a mixture which is then compressed. U.K. Patent No. 1,526,020 to Lifesavers, Inc. discloses a process for the preparation of a tablet containing xylitol utilizing direct compression techniques. In the examples of the patent specification (which disclose the use of xylitol in combination with at least one other polyol), the ratio of xylitol/sorbitol is 1:1 to about 0.43:1 (256:297), and the ratio of xylitol/mannitol is also 1:1. As a consequence, the examples enable only a partial utilization of the anti-cariogenic affect, and advantageous flavoring properties of xylitol, because a major portion of the tablet consists of sorbitol which does not show xylitol's taste and anti-cariogenic qualities.
From a technical perspective, the use of crystalline xylitol produces tablets which are too coarse in many contexts which give rise to a gritty texture and undesirable mouthfeel. The use of milled xylitol (less than 200 micron average particle size) produces a dry blended product (with sorbitol, for example) wherein flowability of the blend is extremely poor (near zero). Tableting machinery equipped with a force feeder is required. Dry blended xylitol and sorbitol is not an acceptable commercial alternative.
The present invention, however, discloses a free flowing, compressible granulate which comprises at least 94% to 98% by weight of xylitol in combination with another physiologically accepted polyol, preferably sorbitol. Sorbitol does not diminish the cooling effect of xylitol (as other constituents may) and also acts as a lubricant in the direct compression context. The granulate is suitable for use as a binding or diluting agent in direct compression techniques. The present invention also contemplates a method for producing such a xylitol-based granulate.
SUMMARY OF THE INVENTION
The present invention contemplates a free flowing, compressible granulate which comprises about 94% to about 98% by weight of xylitol, about 1% to about 5% by weight of a physiologically acceptable polyol other than xylitol, and less than about 1% by weight of water. The polyol does not contribute appreciable moisture to said granulate, nor does it negatively affect the taste profile of xylitol. In a particularly preferred embodiment, the free flowing, compressible granulate comprises about 95% to about 98% by weight of xylitol, about 1.5% to about 3.5% by weight of a physiologically acceptable polyol other than xylitol, and less than about 0.5% by weight of water. The physiologically acceptable polyol of choice is sorbitol, and other polyols such as mannitol, lactitol, maltitol and isomalt can also be used. If sorbitol is utilized, the present invention also contemplates a composition which comprises xylitol, sorbitol and less than about 2% of a physiologically acceptable polyol or polyols other than sorbitol, e.g. mannitol, which does not contribute appreciable moisture, or negatively affect the taste profile of xylitol.
Preferably, the bulk density of the composition of the present invention is between about 0.7 g/cm3 and about 0.8 g/cm3. The average particle size is between about 0.1 mm and about 1.0 mm. The composition exhibits good flow properties, preferably exhibiting a flow range with a maximum of about 15 s/100 g.
The present invention also contemplates a method for the production of a free flowing, compressible granulate wherein finely ground xylitol crystals are agglomerated with a polyol based syrup to obtain granules which are subsequently dried to a water content of less than about 1% by weight. The polyol does not contribute an appreciable amount of moisture, nor does it negatively affect the taste profile of xylitol. The composition, in a preferred embodiment, comprises about 94% to about 98% by weight of xylitol and between about 1% and about 5% by weight of a physiologically acceptable polyol with water present in amounts of less than 1% by weight. In a preferred embodiment of the method of the present invention, the ground xylitol has a particle size of about 0.01 mm to about 0.10 mm, with at least about 50% of said xylitol particles within that range. In a particularly preferred embodiment, the average particle size of the xylitol is about 0.07 mm, with at least about 50% of said xylitol having a particle size of between about 0.02 mm to about 0.10 mm.
The polyol based syrup used for the agglomerating step preferably is based on sorbitol, with a syrup containing between about 50% and about 85% of sorbitol by weight being particularly preferred.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
A. General
The binding and diluting agent of the present invention is a granulated product which has a good flowability and which is prepared by agglomerating crystalline xylitol (ground or otherwise comminuted to a small particle size) by means of polyol based syrup wherein said polyol is a physiologically acceptable polyol other than xylitol. The xylitol is mixed with the syrup at a great speed to obtain a granular product; the granules are subsequently dried to a water content less than 1.0% by weight. The concentration of the physiologically acceptable polyol based syrup is selected so that the obtained granular product contains between about 94% and 98% by weight of xylitol and about 1% to 5% by weight of said physiologically acceptable polyol (other than xylitol). The preferred physiologically acceptable polyol is sorbitol because it does not negatively affect the taste profile of xylitol. The granular product may also contain physiologically acceptable polyols other than xylitol and sorbitol, preferably less than about 2% by weight, provided such polyols do not contribute appreciably to the moisture content, or negatively affect the taste profile of xylitol.
The flowability of the present invention agent can be measured by allowing a sample (200 g) to flow through a hopper (runner pipe dimensions: diameter 8 mm and length 25 mm) on to a balance connected to a recording device. The flowability (s/100 g) of the substance can thus be calculated from the curve so obtained. The flowability should ideally be better than 15 s/100 g. Another procedure for evaluating flowability is the determination of angle of repose: a sample (50 g) is passed slowly through a hopper on to a paper, and the angle defined between the paper and the formed hill is measured. This angle should not exceed 32°.
The bulk density of the substance can be measured by weighing a sample of about 300 g into a measuring cylinder. The sample is poured carefully into the cylinder; the sample is weighed accurately and its volume is recorded. The loose density (LD) can be calculated from this data. Thereafter the sample is vibrated at an amplitude of 1.5 mm, until it does not pack to a smaller volume. The volume is recorded, and the bulk density (also known as tapped density or "TD") is calculated.
Xylitol used as raw material in the production of the binding and diluting agent according to the invention has a purity exceeding 95% by weight, and has been ground or otherwise comminuted to an average particle size of between 0.01 mm to 0.10 mm by means of a suitable mill, such as a hammer mill common in the sugar industry to produce icing sugar.
In a preferred embodiment, sorbitol is added to the xylitol at the granulation stage in the form of sorbitol syrup which may be e.g. hydrogenated starch syrup containing about 50% to 90% by weight of sorbitol on dry substance basis, the remainder consisting of other sugar alcohols. Pure dissolved sorbitol is also suitable for use. Sorbitol syrup is diluted before granulation so that the dry substance content of the solution suits the granulation device. The nozzle structure of the Schugi device, for instance, requires a dry content below 50% by weight. The dry substance content of a commercial sorbitol syrup generally varies from 69% to 71% by weight. The dilution is preferably carried out with water, though a mixture of water and ethanol is also possible. The use of ethanol, however, is restricted by the poor solubility of sorbitol in ethanol.
A preferred method for preparing the present invention consists of granulating the ground or comminuted xylitol together with a small amount of sorbitol syrup by means of a suitable granulation device. The product is dried rapidly in a fluidized bed, for instance. Suitable granulation devices are well known in the art. The dryer may be separate, or the drying may be carried out in a granulator, depending on the type of device. In the granulation device, the ground or comminuted xylitol and the sorbitol syrup added evenly thereto are brought into a rapid movement which effects the agglomeration of the substance together with a small amount of syrup. The grain size can be adjusted by the mixture ratios and the mixing efficiency.
The granulated product is dried rapidly e.g. in a fluidized bed by means of dry air so that the final moisture content is below about 1% by weight, preferably below about 0.5% by weight. A suitable particle size is between about 0.1 mm to about 1 mm whereby about 99% of the granules are within this range. As used herein the term "dry air" refers to air with a water content no more than 7.5 grams of water per cubic meter of air, measured at 20° C.
The product obtained according to the invention is a freely flowing, compressible composition which has excellent compressibility and which withstands storing without getting cloddy. The preferred range of properties for one embodiment are as follows:
Moisture content less than about 1% by weight, with less than 0.5% by weight being particularly preferred
Average grain size (diameter) about 0.1 mm to about 0.6 mm
Xylitol about 95% to about 98% by weight
Sorbitol about 2% to about 3% by weight
Other polyols less than about 2% by weight
Bulk density (TD) about 0.7 to about 0.8 g/cm3
Flowability approximately 15 s/100 g (a hopper with a pipe diameter of 8 mm and a pipe length of 25 mm), or flow angle of maximum 32°
The granulation process is fundamentally different from the dry mixing of two polyols such as xylitol and sorbitol, such as that disclosed by G.B. Patent Nos. 1,526,020. The granulation process results in the crystallization of some of the sorbitol or present onto the surface of the xylitol particles forming fine, needle like protrusions. These needle like protrusions can be seen by electron microscopes, and a photograph showing the granulate of the present invention (with xylitol present in an amount of about 97% by weight, and sorbitol present in an amount of about 3% by weight) is shown in FIG. 1; the needle like crystals can be clearly seen. It is thought that the needle like protrusions are, or at least contribute to, the compressibility of the granulate of the present invention. Blends of xylitol and sorbitol in the proportion covered by the present invention which are simply admixed do not exhibit adequate compressibility and do not exhibit the needle like protrusions in electron micrographs such as those seen in FIG. 1. In order to obtain adequate compressibility with a xylitol/sorbitol admixture, it is necessary to increase the concentration of sorbitol.
Tablets made from pure crystalline xylitol show extremely poor hardness. At a force of 25 kN, 100% xylitol tablets exhibited a crushing strength less than 25 N. Only when sorbitol was present in amounts exceeding 40% by weight did the crushing strength exceed 100 N at a crushing strength of 25 kN. The present invention allows the use of high concentrations of xylitol thereby taking full advantage of its taste, metabolic and other advantages.
Example 1: Production of Xylitol Powder
Crystalline xylitol (purity over 95% by weight) was ground by means of a turbo mill (Bauermeister, manufacturer Gebr. Bauermeister & Co., Hamburg, West Germany) to an average particle size of about 0.07 mm. Over 50% of the particles were within the range from about 0.02 mm to about 0.10 mm, and the powder did not contain any particles exceeding 0.125 mm, nor a dusty fraction.
Example 2: Granulation of Xylitol Powder
A xylitol powder produced according to Example 1 and a 40% by weight sorbitol syrup solution (containing 34% by weight of sorbitol, and less than 5.7% of other polyols) were introduced into a granulator (Schugi, manufacturer Schugi, BV, Lelystad, Holland) at a speed of 800 kg/hour (powder) and 50 1/hour (syrup solution) at a temperature of 60° C. The spraying pressure was 2 bar and the rotative velocity 3,000 r/min, whereby grains having an average diameter of 0.42 mm were obtained (over 50% within the range of 0.2 to 0.6 mm). The resultant grains were dried with a fluidized-bed dryer (Schugi, manufacturer Schugi, BV, Lelystad, Holland). Granulate was fed into the dryer at a rate of 820 kg/h, and 10,000 m3 /hour of dry air was introduced therein. The temperature of the drying air in the first quarter of the dryer was 45° C. and in the second quarter 35° C.; in the last two quarters of the dryer the temperature was room temperature, i.e. 20° C. to 25° C. The moisture content of the product was about 0.3% by weight, and the bulk density (TD) was about 0.74 g/ml.
The composition of the product was as follows:
______________________________________                                    
Xylitol              97%                                                  
Sorbitol             2%                                                   
Other Polyols        approx. 1%                                           
Moisture             0.3%                                                 
______________________________________                                    
The flowability of the granulate produced according to Example No. 2 was extremely good (flow rate 12 s/100 g; flow angle 30°), and the properties of the granulate did not change during storage (75 days, 18° C.).
Example 3: Compression of Tablets
The granulate produced according to Example 2 was compressed to tablets by means of an eccentric press (Korsch EK-O/DMS; manufacturer Korch OHC Maschinenfabrick, Berlin, West Germany). Magnesium stearate (1%) was used as an additive. The diameter of the tablet was 11 mm and weight 500 mg. The crushing strength of tablets manufactured by different compression forces was determined in accordance with the instructions of the European Pharmacopean. The results are shown in Table 1.
              TABLE I                                                     
______________________________________                                    
Compression Force                                                         
                Crushing Strength                                         
______________________________________                                    
 5 kN           46 N                                                      
10 kN           66 N                                                      
15 kN           88 N                                                      
20 kN           108 N                                                     
______________________________________                                    
Example 4: Compression of Tablets
A granulate produced according to Example 2 was compressed to double-convex tablets by means of a rotation machine (Manesty D 3; manufacturer, Manesty Machines, Liverpool, England). Magnesium stearate (1%) was used as an additive. The diameter of the tablet was 15 mm and weight 907 mg. The crushing strength of the tablet (European Pharmacopea) was 127 N; the weight loss in friability tests was 0.71%.
Tablets prepared in Examples 3 and 4 had acceptable mouthfeel, initial hardness and friability.
The foregoing general discussion and experimental examples are intended to be illustrative of the present invention, and are not to be considered as limiting. Other variations within the spirit and scope of this invention are possible, and will present themselves to those skilled in the art.

Claims (5)

We claim:
1. A method for the production of a free flowing, compressible granulate which comprises the steps of
agglomerating crystalline xylitol, ground to a reduced particle size, with a physiologically acceptable polyol based syrup,
wherein said physiologically acceptable polyol will not contribute appreciable moisture to said granulate or appreciably negatively affect the taste profile of xylitol,
to obtain granules,
and wherein said granules comprise 94% to 98% by weight of xylitol and 1% to 5% by weight of said physiologically acceptable polyol; and
drying said granules so that the water content is less than 1% by weight.
2. The method of claim 1 wherein the average particle size of said crystalline xylitol is between 0.01 mm to 0.1 mm with at least 50% of said xylitol being within the range of between 0.01 mm to 0.1 mm.
3. The method of claim 2 wherein the average particle size of said crystalline xylitol is 0.07 mm in diameter, with at least 50% of said xylitol having a particle size of between 0.02 mm to 0.10 mm.
4. The method of claim 3 wherein said syrup contains between 50% and 85% by weight of sorbitol.
5. The method of claim 4 wherein said granulate comprises 94% to 98% by weight of xylitol, and between 1% and 5% by weight of sorbitol.
US08/616,182 1988-01-11 1996-03-15 Process for the production of a xylitol-based binding and diluting agent Expired - Lifetime US5616361A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/616,182 US5616361A (en) 1988-01-11 1996-03-15 Process for the production of a xylitol-based binding and diluting agent

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FI880092A FI880092A (en) 1988-01-11 1988-01-11 FOGNINGSKONSTRUKTION AV ELDSTADSDELAR.
FI88092 1988-02-25
US31476689A 1989-02-23 1989-02-23
US08/079,794 US5536526A (en) 1988-01-11 1991-03-20 Xylitol-based binding and diluting agent and a process for the production thereof
US08/616,182 US5616361A (en) 1988-01-11 1996-03-15 Process for the production of a xylitol-based binding and diluting agent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/079,794 Continuation US5536526A (en) 1988-01-11 1991-03-20 Xylitol-based binding and diluting agent and a process for the production thereof

Publications (1)

Publication Number Publication Date
US5616361A true US5616361A (en) 1997-04-01

Family

ID=27241257

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/079,794 Expired - Lifetime US5536526A (en) 1988-01-11 1991-03-20 Xylitol-based binding and diluting agent and a process for the production thereof
US08/616,182 Expired - Lifetime US5616361A (en) 1988-01-11 1996-03-15 Process for the production of a xylitol-based binding and diluting agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/079,794 Expired - Lifetime US5536526A (en) 1988-01-11 1991-03-20 Xylitol-based binding and diluting agent and a process for the production thereof

Country Status (1)

Country Link
US (2) US5536526A (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958471A (en) * 1994-11-08 1999-09-28 Merck Patent Gesellschaft Mit Beschrankter Haftung Spray dried polyol composition and method of making
US6039813A (en) * 1989-06-07 2000-03-21 Xyrofin Oy Fructose-based granulated product and a process for the production thereof
US6083527A (en) * 1998-11-05 2000-07-04 Thistle; Robert Breath mint with tooth decay and halitosis prevention characteristics
WO2001019208A1 (en) * 1999-09-10 2001-03-22 Südzucker Aktiengesellschaft Directly compressable raw material for tablets
US6207138B1 (en) * 1997-05-19 2001-03-27 Colgate-Palmolive Company Fluoride free dental remineralization
KR20030056236A (en) * 2001-12-27 2003-07-04 김현 Sugar content and manufacturing method for the sugar content
US20030138485A1 (en) * 1998-01-14 2003-07-24 Daiichi Pharmaceutical Co., Ltd. Disintegrant
WO2004067595A2 (en) * 2003-01-29 2004-08-12 Spi Polyols, Inc. Compositions of polyol granules and processes of manufacture
US6821535B2 (en) 2000-02-03 2004-11-23 Xyrofin Oy Process for hard panning of chewable cores and cores produced by the process
US20050272961A1 (en) * 2004-03-26 2005-12-08 Bemiller James N Processes for the production of xylitol
US20060276328A1 (en) * 1997-10-20 2006-12-07 Vierheilig Albert A Process for making, and use of, anionic clay materials
EP1852109A1 (en) * 2005-05-08 2007-11-07 Beijing Jianli Pharmaceutical Co. Ltd. Xylitol granules capable of directly being pressed into tablets and preparation process thereof
US7625728B2 (en) 1990-01-15 2009-12-01 Danisco Sweeteners Oy Process for the simultaneous production of xylitol and ethanol
US20100255307A1 (en) * 2007-07-27 2010-10-07 Cargill Inc. Micronization of polyols
US20130028973A1 (en) * 2004-05-24 2013-01-31 Nycomed Pharma As Particulate comprising a calcium-containing compound and a sugar alcohol
US10435721B2 (en) 2016-12-21 2019-10-08 Creatus Biosciences Inc. Xylitol producing metschnikowia species

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536526A (en) * 1988-01-11 1996-07-16 Cultor Ltd. Xylitol-based binding and diluting agent and a process for the production thereof
US5846568A (en) * 1996-09-19 1998-12-08 Xyrofin Oy Directly compressible lactitol and method
US6001399A (en) * 1997-03-19 1999-12-14 Cultor Food Science, Inc. Polydextrose as a fat absorption inhibitor in fried foods
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
ATE346589T1 (en) * 1997-10-15 2006-12-15 Merck Patent Gmbh PRODUCTION OF A DIRECTLY COMPRESSABLE TABLETTING AID
US6270790B1 (en) * 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
AU1323400A (en) * 1998-10-27 2000-05-15 Fuisz Technologies Ltd. Microparticles containing peg and/or peg glyceryl esters
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
EP1621187A1 (en) * 2004-07-26 2006-02-01 AstraZeneca AB Pharmaceutical multiparticulate tablet formulations and process for their preparation
US20060062833A1 (en) * 2004-09-22 2006-03-23 Cima Labs Inc. Wound dressing
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
CN102448499A (en) * 2009-04-27 2012-05-09 药效学应用实验室股份有限公司 Oral ibuprofen lysinate suspension
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
WO2021223824A1 (en) * 2020-05-08 2021-11-11 Fertin Pharma A/S Flowpack for oral delivery of active ingredients
CN114158737A (en) * 2021-12-17 2022-03-11 浙江华康药业股份有限公司 Method for preventing mixture of xylitol and calcium aspartate from caking

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2336123A1 (en) * 1975-12-24 1977-07-22 Life Savers Inc PRESSED CHEW TABLE CONTAINING XYLITOL AND ONE OR MORE POLYOLS AND ITS PREPARATION PROCESS
FR2380777A1 (en) * 1977-02-17 1978-09-15 Merck Patent Gmbh GRANULES CONTAINING ASCORBIC ACID AND THEIR PREPARATION PROCESS
EP0193651A2 (en) * 1985-03-06 1986-09-10 Cultor Ltd. Binder-diluent composition and method
US5385749A (en) * 1990-12-14 1995-01-31 Roquette Freres Directly compressible pulverulent composition and a process for obtaining the same
US5536526A (en) * 1988-01-11 1996-07-16 Cultor Ltd. Xylitol-based binding and diluting agent and a process for the production thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2336123A1 (en) * 1975-12-24 1977-07-22 Life Savers Inc PRESSED CHEW TABLE CONTAINING XYLITOL AND ONE OR MORE POLYOLS AND ITS PREPARATION PROCESS
GB1526020A (en) * 1975-12-24 1978-09-27 Life Savers Inc Confectionary tablets
FR2380777A1 (en) * 1977-02-17 1978-09-15 Merck Patent Gmbh GRANULES CONTAINING ASCORBIC ACID AND THEIR PREPARATION PROCESS
EP0193651A2 (en) * 1985-03-06 1986-09-10 Cultor Ltd. Binder-diluent composition and method
US5536526A (en) * 1988-01-11 1996-07-16 Cultor Ltd. Xylitol-based binding and diluting agent and a process for the production thereof
US5385749A (en) * 1990-12-14 1995-01-31 Roquette Freres Directly compressible pulverulent composition and a process for obtaining the same

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039813A (en) * 1989-06-07 2000-03-21 Xyrofin Oy Fructose-based granulated product and a process for the production thereof
US7625728B2 (en) 1990-01-15 2009-12-01 Danisco Sweeteners Oy Process for the simultaneous production of xylitol and ethanol
US5958471A (en) * 1994-11-08 1999-09-28 Merck Patent Gesellschaft Mit Beschrankter Haftung Spray dried polyol composition and method of making
US6207138B1 (en) * 1997-05-19 2001-03-27 Colgate-Palmolive Company Fluoride free dental remineralization
US20060276328A1 (en) * 1997-10-20 2006-12-07 Vierheilig Albert A Process for making, and use of, anionic clay materials
US20030138485A1 (en) * 1998-01-14 2003-07-24 Daiichi Pharmaceutical Co., Ltd. Disintegrant
US20050152973A1 (en) * 1998-01-14 2005-07-14 Daiichi Pharmaceutical Co., Ltd. Disintegrant
US6083527A (en) * 1998-11-05 2000-07-04 Thistle; Robert Breath mint with tooth decay and halitosis prevention characteristics
US6890559B1 (en) * 1999-09-10 2005-05-10 Sudzucker Aktiengesellschaft Mannheim/Ochsenfurt Directly compressible raw material for tablets
WO2001019208A1 (en) * 1999-09-10 2001-03-22 Südzucker Aktiengesellschaft Directly compressable raw material for tablets
US6821535B2 (en) 2000-02-03 2004-11-23 Xyrofin Oy Process for hard panning of chewable cores and cores produced by the process
KR20030056236A (en) * 2001-12-27 2003-07-04 김현 Sugar content and manufacturing method for the sugar content
US7582154B2 (en) * 2003-01-29 2009-09-01 Corn Products International, Inc. Compositions of polyol granules and processes of manufacture
WO2004067595A2 (en) * 2003-01-29 2004-08-12 Spi Polyols, Inc. Compositions of polyol granules and processes of manufacture
US20060078663A1 (en) * 2003-01-29 2006-04-13 Spi Polyols, Inc. Compositions of polyol granules and processes of manufacture
WO2004067595A3 (en) * 2003-01-29 2004-12-09 Spi Polyols Inc Compositions of polyol granules and processes of manufacture
US7598374B2 (en) 2004-03-26 2009-10-06 Purdue Research Foundation Processes for the production of xylitol
US20050272961A1 (en) * 2004-03-26 2005-12-08 Bemiller James N Processes for the production of xylitol
US20130028973A1 (en) * 2004-05-24 2013-01-31 Nycomed Pharma As Particulate comprising a calcium-containing compound and a sugar alcohol
US10357460B2 (en) * 2004-05-24 2019-07-23 Takeda As Particulate comprising a calcium-containing compound and a sugar alcohol
EP1852109A1 (en) * 2005-05-08 2007-11-07 Beijing Jianli Pharmaceutical Co. Ltd. Xylitol granules capable of directly being pressed into tablets and preparation process thereof
EP1852109A4 (en) * 2005-05-08 2010-05-12 Beijing Jianli Pharmaceutical Xylitol granules capable of directly being pressed into tablets and preparation process thereof
US20100255307A1 (en) * 2007-07-27 2010-10-07 Cargill Inc. Micronization of polyols
US10435721B2 (en) 2016-12-21 2019-10-08 Creatus Biosciences Inc. Xylitol producing metschnikowia species
US11473110B2 (en) 2016-12-21 2022-10-18 Creatus Biosciences Inc. Xylitol producing Metschnikowia species

Also Published As

Publication number Publication date
US5536526A (en) 1996-07-16

Similar Documents

Publication Publication Date Title
US5616361A (en) Process for the production of a xylitol-based binding and diluting agent
EP0561815B1 (en) Directly compressible xylitol and method
US5098730A (en) Dietetic sweetening composition
US5939091A (en) Method for making fast-melt tablets
JP2546068B2 (en) Preparation containing L-carnitine
US5846568A (en) Directly compressible lactitol and method
CA2955849C (en) Sugar compositions for tableting by direct compression
JP4748627B2 (en) Excipient
EP0009325A1 (en) Erythritol cointaining anti-caries compositions
US6372271B1 (en) Sugar-free dragee chewing sweets
US4572916A (en) Tablets
JPS6239133B2 (en)
JPH06504448A (en) Water-soluble delivery system for hydrophobic liquids
JPH08191665A (en) Chewing gum composition improved in functional characteristics and its preparation
SK15492002A3 (en) Confectionery product having an enhanced cooling effect
EP0844881B1 (en) Laxative comprising lactitol and psyllium
RU2222224C2 (en) Raw material for pressed product adaptable for direct pressing process
GB2214079A (en) Chewable, non-gritty calcium citrate tablet
US20050152972A1 (en) Soft chewable anesthetic lozenges
WO2001017503A2 (en) Sugar compositions
JP3597901B2 (en) Powdered xylitol in which caking has been prevented, method for producing the same, and method for preventing caking of powdered xylitol
EP1011631A1 (en) Antacid composition
JP2003095982A (en) Improver for feeling on tongue of sorbitol tablet molding

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: XYROFIN OY, FINLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CULTOR LTD.;REEL/FRAME:008773/0517

Effective date: 19970808

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: XYROFIN OY, FINLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DANISCO FINLAND OY;REEL/FRAME:012530/0715

Effective date: 20010430

AS Assignment

Owner name: DANISCO SWEETENERS OY, FINLAND

Free format text: CHANGE OF NAME;ASSIGNOR:XYROFIN OY;REEL/FRAME:013542/0808

Effective date: 20011217

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

REMI Maintenance fee reminder mailed